Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Regulation

Leqembi marks fifth disagreement between FDA and CHMP on neurology medicines

Next up for comparison will be Alzheimer’s therapy donanemab, which FDA approved in June and CHMP is reviewing

July 27, 2024 12:57 AM UTC
Updated on Jul 27, 2024 at 3:44 AM UTC

CHMP issued a negative opinion Friday recommending against approval of Leqembi to treat early Alzheimer’s disease, the fifth time in the last several years that the European regulator has rejected a drug for a neurodegenerative disease that FDA had approved.

Eisai Co. Ltd. (Tokyo:4523), which is responsible for the application for Leqembi lecnemab, said it would request a re-examination of the decision. It has a 50-50 cost and profit-sharing agreement with Biogen Inc. (NASDAQ:BIIB) on the therapy...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article